Dr. Jun Deng has been a driving force at Joyance Partners since its formation in 2017, where she played a pivotal role in shaping the fund's strategic vision and remarkable growth trajectory. A scientist by training and an innovator at heart, Dr. Deng leverages her role as an Investment Partner to identify and nurture high-growth companies across the spectrum, overseeing all of Joyance’s healthcare investments and achieving multiple successful exits, including Volumetric (acquired by 3D Systems), Osmosis (acquired by Reed Elsevier), and Loop Genomics (acquired by Element Biosciences). Beyond her investment successes, Dr. Deng serves on the boards of numerous companies and mentoring at programs like Endless Frontier Labs at NYU, BioDesign at Stanford, and Singularity University. She is also a strategic partner at Healthtech Capital.